The Current and Evolving Landscape of First‐Line Treatments for Advanced Renal Cell Carcinoma

Agents targeting the vascular endothelial growth factor (VEGF) and its receptors (VEGFRs), as well as the mammalian target of rapamycin (mTOR) and immune checkpoint receptor programmed death 1 (PD‐1) signaling pathway have improved clinical outcomes for patients with advanced renal cell carcinoma (R...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncologist
Autores principales: Calvo, Emiliano, Porta, Camillio, Grünwald, Viktor, Escudier, Bernard
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley & Sons, Inc. 2018
Materias:
Genitourinary Cancer
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6519762/
https://ncbi.nlm.nih.gov/pubmed/30158285
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0267
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares